Psychotic Disorders Clinical Trial
— FYFOfficial title:
Face Your Fears: An Assessor-blinded, RCT Evaluating the Effectiveness of Cognitive Behavioural Virtual Reality Therapy Versus Cognitive Behavioural Therapy in Patients With Schizophrenia Spectrum Disorders.
Verified date | June 2024 |
Source | Mental Health Services in the Capital Region, Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is a randomised, assessor-blinded parallel-groups superiority clinical trial fulfilling the CONSORT criteria for non-pharmacological treatment. A total of 256 patients will be allocated to either Cognitive Behavioural Virtual Reality Therapy plus treatment as usual, versus traditional CBT for psychosis plus treatment as usual. All participants will be assessed at baseline and 3- and 9 months post baseline. A stratified block-randomisation with concealed randomisation sequence will be conducted. Independent assessors blinded to the treatment will evaluate outcome. Analysis of outcome will be carried out with the intention to treat principles.
Status | Active, not recruiting |
Enrollment | 258 |
Est. completion date | August 2024 |
Est. primary completion date | March 21, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age 18 - years 2. Ability to give informed consent 3. A schizophrenia spectrum disorder (ICD-10 code: F20 -F29) 4. Green Paranoid Thought Scale total score = 40 Exclusion Criteria: 1. Rejecting informed consent 2. A diagnosis of organic brain disease 3. IQ of 70 or lower (known mental retardation as assessed by medical record) 4. A command of spoken Danish or English inadequate for engaging in therapy 5. Inability to tolerate the assessment process |
Country | Name | City | State |
---|---|---|---|
Denmark | Copenhagen Research Center for Mental Health - CORE | Copenhagen | Hellerup |
Lead Sponsor | Collaborator |
---|---|
Mental Health Services in the Capital Region, Denmark | Central Denmark Region, Mental Health Services in the North Denmark Region |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | CDSS (Calgary Depression Scale for Schizophrenia) | Minimum score: 0 Maximum score: 9*3 = 27. Higher score means worse outcome. | 3 and 9 months from inclusion | |
Other | BNSS (Brief Negative Symptom Scale) | 13 items with a score from minimum 0 to maximum 6 for each item. Higher score means worse outcome. | 3 and 9 months from inclusion | |
Other | COGDIS (Cognitive disturbances scale) | Score of 0-6 indicate a range. Minimum score: 0 Maximum score: 9*6 = 54. Higher score means worse outcome. Trait phenomenons are coded with a "7", unknown degree of severly is coded with a "8" and uncertainty whether the symptom is present is coded with a "9". | 3 and 9 months from inclusion | |
Other | SAPS (Scale for the Assesment of Positive symptoms) | Composite total score: Minimum score: 0 Maximum score: 30*5 = 150. Higher score means worse outcome.
Global score: Minimum score: 0 Maximum score: 4*5 = 20. Higher score means worse outcome. |
3 and 9 months from inclusion | |
Other | Trustworthiness Scale | Minimum score: -3*42=-126 Maximun score: +3*42=126. Higher positive score means better outcome. Higher negative score means worse outcome. | 3 and 9 months from inclusion | |
Other | DACOBS (Davos Assessment of the Cognitive Biases Scale) | Total score: Minimum score: 1*42=42. Maximum score:7*42=294. Higher score means worse outcome.
Subscales of: Jumping to conclusions bias: Item 3+8+16+18+25+30 Belief Inflexibility bias: Item 13+15+26+34+38+41 Attention for Threat bias: Item 1+2+6+10+20+37 External Attribution bias: Item 7+12+17+22+24+29 Social Cognition problems: Item 4+9+11+14+19+39 Subjective Cognitive problems: Item 5+21+28+32+36+40 Safety behaviors: Item 23+27+31+33+35+42 |
3 and 9 months from inclusion | |
Other | SIDAS (Suicidal Ideation Attributes Scale) | Minimum score: 0. Maximum score: 50. Item 2 has a reverse score. Higher score means worse outcome. | 3 and 9 months from inclusion | |
Other | BCSS (The Brief Core Schema Scales: Beliefs about self and others) | Items with negative belief of self and others: Minimum score: 0. Maximum score: 2*6*4= 48. Higher score means worse outcome.
Items with Positive belief of self and others: Minimum score: 0. Maximum score: 2*6*4= 48. Higher score means better outcome. |
3 and 9 months from inclusion | |
Other | SSPA (Social Skills Performance Assessment) | Scene I: Minimum score: 1*8=8. Maximum score: 5*8:40. Higher score means better outcome.
Scene II: Minimum score: 1*9=9. Maximum score: 5*9:45. Higher score means better outcome. |
3 and 9 months from inclusion | |
Other | TALE (Trauma And Life Events checklist) | Baseline measure | ||
Other | IBT (Intentionality Bias Task) | 3 and 9 months from inclusion | ||
Other | (R-GPTS) Revised Green Paranoid Thought Scale | Minimum total score: 0. Maximum total score: 4*18=72. Part A (Ideas of social reference) minimum score: 0 and maximum score: 4*8=32. Part B (Ideas of persecution) minimum score 0 and maximum score: 4*10=40. Part B score = or > 18 are assumed to be threshold for development of delusion. Higher score means worse outcome. | 3 and 9 months from inclusion | |
Other | GSE (General Self Efficacy Scale) | Minimum score: 1*10=10. Maximum score: 4*10=40. Higher score means better outcome. | 3 and 9 months from inclusion | |
Other | Big-5 (personality traits) | 5 spectrums of personality traits assessed with 5 items each.
Minimum score for each personality trait: Minimum score: 1*5=5. Maximum score: 5*5=25 Certain items have reverse scores. |
3 and 9 months from inclusion | |
Other | EQ-5D-5L (EuroQOL five dimensions questionnaire) | Scoring the descriptive system:
Minimum score: 1-1-1-1-1. Maximum score: 5-5-5-5-5. Higher score means worse outcome. Scoring the VAS: Minimum score: 0. Maximum score: 100. Higher score means better outcome. |
3 and 9 months from inclusion | |
Other | WHO (World Health Organization 5) | Minimum score: 0. Maximum score: 5*5*4=100. Higher score means better outcome. | 3 and 9 months from inclusion | |
Other | CSQ (Client Satisfaction Questionnaire) | 3 months follow-up | ||
Other | SFS (The Social Functioning Scale) | Minimum raw score: 0. Maximum raw score: 15+9+39+45+66+39+19=223. Higher score means better outcome. | 3 and 9 months from inclusion | |
Primary | (GPTS) Green Paranoid Thought Scale Part B: Ideas of persecution. | The primary outcome is level of ideas of persecution measured with Green Paranoid Thought Scale at cessation of treatment at 3-months. The Green Paranoid Thought Scale has displayed good reliability and validity in patients with psychosis, displaying paranoid, persecutory delusions, and has also been used in patients at-risk for psychosis showing subthreshold psychotic symptoms.
Minimum total score: 32. Maximum total score: 160. Part A (Ideas of social reference) minimum score: 16 and maximum score: 80. Part B (ideas of persecution) minimum score 16 and maximum score: 80. Part B score = or > 45 are assumed to be threshold for development of persecutory delusion. Higher score means worse outcome. |
3 months from inclusion | |
Secondary | SIAS (Social Interaction Anxiety Scale) | Minimum score: 0 Maximum score: 20*4=80. Item 5,9 and 11 have reverse score. Higher score means worse outcome. | 3 and 9 months from inclusion | |
Secondary | SBQ (Safety Behaviour Questionnaire) | Minimum score: 0. Maximum score is in theory unlimited depending on the number of identified, specific safety behaviours. | 3 and 9 months from inclusion | |
Secondary | PSP (Personal and Social Performance Scale) | Minimum score: 1 Maximum score: 100. Higher score means better outcome. | 3 and 9 months from inclusion | |
Secondary | CANTAB ERT (Emotion Recognition Task) | 3 and 9 months from inclusion | ||
Secondary | (GPTS) Green Paranoid Thought Scale Part A: Ideas of social reference | Minimum total score: 32. Maximum total score: 160. Part A (Ideas of social reference) minimum score: 16 and maximum score: 80. Part B (Ideas of persecution) minimum score 16 and maximum score: 80. Part B score = or > 45 are assumed to be threshold for development of delusion. Higher score means worse outcome. | 3 and 9 months from inclusion | |
Secondary | (GPTS) Green Paranoid Thought Scale Part B: Ideas of persecution | Minimum total score: 32. Maximum total score: 160. Part A (Ideas of social reference) minimum score: 16 and maximum score: 80. Part B (Ideas of persecution) minimum score 16 and maximum score: 80. Part B score = or > 45 are assumed to be threshold for development of delusion. Higher score means worse outcome. | 9 months from inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Terminated |
NCT03230097 -
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
|
Phase 2 | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Recruiting |
NCT02874573 -
Tocilizumab in Schizophrenia
|
Phase 1 | |
Terminated |
NCT02584114 -
Brain Effects of Memory Training in Early Psychosis
|
N/A | |
Completed |
NCT02906553 -
The Role of Nitric Oxide in Cognition in Schizophrenia
|
N/A | |
Completed |
NCT01981356 -
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
|
Phase 0 | |
Terminated |
NCT02841956 -
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Recruiting |
NCT02848469 -
Irish Omega-3 Study
|
Phase 2 | |
Recruiting |
NCT02009969 -
Serial Comparisons of Abdominal and Neurological MRI Scans
|
N/A | |
Completed |
NCT02648321 -
Motivational Intervention for Physical Activity in Psychosis
|
N/A | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
Completed |
NCT00455234 -
Rapid Tranquillization Trial: TREC-India II
|
Phase 3 | |
Completed |
NCT00844922 -
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
|
Phase 2 | |
Completed |
NCT00130923 -
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
|
Phase 4 | |
Completed |
NCT00130676 -
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
|
Phase 3 |